A new study has explored the experiences of people with motor neuron disease (MND) when deciding whether to have genetic testing. The findings highlight the importance of clear information and tailored support to help individuals make informed choices about testing and its implications for themselves and their families, while respecting their decision-making needs.

Genetic testing can identify whether MND is linked to a change in a known gene, which may be inherited. A positive result can influence eligibility for research studies and access to specific treatments, and inform relatives’ decisions about predictive or reproductive testing, thereby addressing their needs and concerns.

Exploring experiences and needs around genetic testing

The study, published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, involved interviews with 14 people living with MND across the UK. Some participants had undergone genetic testing, while others had not. Researchers asked about their experiences, what information they received, and what support they felt was needed. Responses were analysed to identify common themes.

Mixed experiences and reasons for testing

Participants reported varied experiences:

  • Limited information: Some people who had not been tested knew very little about what genetic testing involved.
  • Mixed support: Among those tested, some described positive experiences with clear explanations, while others felt poorly informed and uncertain about what their results meant for themselves or their families.
  • Unanswered questions: Even after receiving results, some people still had unresolved concerns.

Reasons for choosing genetic testing included contributing to research, understanding the cause of symptoms, exploring treatment options, and providing helpful information for family planning. Reasons for declining testing included concerns about family members’ emotional responses, financial implications such as insurance, and a belief that results would not be helpful given the limited treatment options currently available.

What information and support do people want?

Participants agreed that anyone considering genetic testing should receive:

  • Clear explanations of the process, the genes involved, and how they can be inherited.
  • Information on links between MND and other conditions.
  • Details of possible outcomes and what each result means for individuals and families.
  • Guidance on implications for research participation and treatment access.
  • Resources to share with family members and opportunities to ask questions.

Timing and delivery were also important. Discussions should be led by knowledgeable healthcare professionals with whom patients have a trusting relationship.

What does this mean for people with MND?

Findings from this study have informed the development of patient decision aids, resources designed to help people with MND and their families understand genetic testing options and consider what matters most to them. These tools aim to support informed, personalised decision-making.

This research snapshot was created using the University of Sheffield’s Readable Research series, which turns technical science into clear, meaningful updates for the MND community. A lay summary of the above research paper is available here.

Original study:
Howard J, Allen S et al. Exploring the needs and preferences of people with amyotrophic lateral sclerosis (ALS) when making genomic testing decisions: an interview study.
Published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, February 2025.
DOI: 10.1080/21678421.2025.2469727